| Literature DB >> 29373243 |
A Regueiro-García1, S Fariña-Nogueira2, J Á Porto-Arceo3, J M Couselo-Sánchez2.
Abstract
Chronic granulomatous disease is a primary immunodeficiency caused by mutations in any one of the five components of the NADPH oxidase in phagocytic leucocytes. This causes impaired microbial killing, which leads to severe life-threatening bacterial and fungal infections. Currently, allogenic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for chronic granulomatous disease, although gene therapy may provide a new therapeutic option for the treatment of patients with CGD. Haploidentical HSCT provides a potentially curative treatment option for patients who lack a suitably HLA-matched donor, but only a few cases have been reported in the literature. Herein, we report a boy with X-linked chronic granulomatous disease treated successfully by haploidentical HSCT with post-transplant cyclophosphamide using a treosulfan-based conditioning regimen.Entities:
Keywords: Chronic granulomatous disease; Haploidentical; Hematopoietic stem cell transplantation; Immunologic deficiency syndromes; Treosulfan
Mesh:
Substances:
Year: 2018 PMID: 29373243 DOI: 10.1016/j.aller.2017.09.020
Source DB: PubMed Journal: Allergol Immunopathol (Madr) ISSN: 0301-0546 Impact factor: 1.667